Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

November 30, 2009

Study Completion Date

May 31, 2010

Conditions
Hepatocellular CarcinomaLiver Cancer
Interventions
DEVICE

Yttrium-90 microspheres (Therasphere MDS Nordion)

Y-90 is incorporated into very tiny glass beads (microspheres: Therasphere MDS Nordion) and is injected into the liver tumor through the hepatic arteries, which are responsible for the feeding of the neoplastic liver tissue. Since the microspheres are unable to pass through the micro-vasculature of the liver parenchyma and tumor they are trapped at those sites and exert a local radio-therapeutic effect.

Trial Locations (1)

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Milan

All Listed Sponsors
collaborator

Gastro Intestinal Surgery and Liver Transplantation

UNKNOWN

collaborator

The Hepato-Oncology Group: Department of Surgery, Medicine and Radiology

UNKNOWN

lead

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER

NCT00910572 - Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter